Clinical Trial

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-08-07; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-10-16
Trial Details
NCT Number NCT07116616
Lead Sponsor ModernaTX, Inc.
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 166 participants
Start Date 2025-09-30
Primary Completion 2030-06-17 (estimated)
Study Completion 2032-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-24